BCL2 and diffuse large B-cell lymphoma: However, at least MYC mutations [13] nor BCL2 mutations [14] have been clearly associated with inferior survival outcomes in patients with newly-diagnosed GCB DLBCL/HGBL treated with R-CHOP.